Suppr超能文献

三阴性乳腺癌:具有临床前模型疗效的 circRNAs 的鉴定。

Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical Models.

机构信息

Roche Pharma Research and Development, Roche Innovation Center, Penzberg, Germany;

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland

出版信息

Cancer Genomics Proteomics. 2023 Mar-Apr;20(2):117-131. doi: 10.21873/cgp.20368.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with insufficient options for therapy. In order to identify new targets and treatment modalities we searched the literature for circular RNAs (circRNAs) which mediate efficacy in TNBC-related in vivo preclinical models. In addition to 5 down-regulated circRNAs which modulate tumor-suppressive pathways, we identified 15 up-regulated circRNAs. Down- and up-regulated refers to expression in corresponding non-transformed cells and tissues. The up-regulated circRNAs comprise five transmembrane receptors and secreted proteins as targets, five transcription factors and transcription-associated targets, four cell-cycle related circRNAs and one involved in paclitaxel resistance. In this review article we discuss drug-discovery related aspects and modalities of therapeutic intervention. Down-regulated circRNAs can be reconstituted by re-expression of corresponding circRNAs in tumor cells or up-regulation of corresponding targets. Up-regulated circRNAs can be inhibited by small-interfering RNA (siRNA) or short hairpin RNA (shRNA)-based approaches or inhibition of the corresponding targets with small molecules or antibody-related moieties.

摘要

三阴性乳腺癌(TNBC)是一种侵袭性的乳腺癌亚型,治疗选择有限。为了寻找新的治疗靶点和方法,我们在文献中搜索了circRNAs(环状 RNA),这些circRNAs 在与 TNBC 相关的体内临床前模型中具有疗效。除了 5 个下调的circRNAs 调节肿瘤抑制途径外,我们还鉴定了 15 个上调的circRNAs。下调和上调是指在相应的非转化细胞和组织中的表达。上调的 circRNAs 包括五个跨膜受体和分泌蛋白作为靶点,五个转录因子和转录相关靶点,四个细胞周期相关的 circRNAs 和一个与紫杉醇耐药相关的 circRNA。在这篇综述文章中,我们讨论了与药物发现相关的方面和治疗干预的模式。下调的 circRNAs 可以通过在肿瘤细胞中重新表达相应的 circRNAs 或上调相应的靶点来重建。上调的 circRNAs 可以通过 siRNA 或 shRNA 方法抑制,或通过小分子或抗体相关部分抑制相应的靶点。

相似文献

引用本文的文献

本文引用的文献

1
Nucleic acid delivery for therapeutic applications.治疗应用的核酸递送。
Adv Drug Deliv Rev. 2021 Nov;178:113834. doi: 10.1016/j.addr.2021.113834. Epub 2021 Sep 4.
4
The emerging role of WWP1 in cancer development and progression.WWP1在癌症发生发展中的新作用。
Cell Death Discov. 2021 Jun 21;7(1):163. doi: 10.1038/s41420-021-00532-x.
5
Noncoding RNA therapeutics - challenges and potential solutions.非编码 RNA 治疗学——挑战与潜在解决方案。
Nat Rev Drug Discov. 2021 Aug;20(8):629-651. doi: 10.1038/s41573-021-00219-z. Epub 2021 Jun 18.
9
Advances in targeting 'undruggable' transcription factors with small molecules.小分子靶向“不可成药”转录因子的研究进展。
Nat Rev Drug Discov. 2021 Sep;20(9):669-688. doi: 10.1038/s41573-021-00199-0. Epub 2021 May 18.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验